Video

Urology Times 50 Innovations Series: Stem cell–derived therapy for stress urinary incontinence

Author(s):

Urology Times staff

"The newest frontier of therapy for stress incontinence is regenerative medicine and stem cell–based therapies," says Melissa R. Kaufman, MD, PhD, FACS.

Urology Times is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence. . Dr. Kaufman is a Professor of urology, Patricia and Rodes Hart Endowed Chair of Urologic Surgery, and Chief of Reconstructive Urology and Pelvic Health at Vanderbilt University Medical Center, Nashville, Tennessee.

Related Videos
Karyn S. Eilber, MD, answers a question during a Zoom video interview
Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
Colin Goudelocke, MD, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Related Content
First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
April 24th 2025

First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

Hannah Clarke
"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Gene therapy shows encouraging efficacy for overactive bladder
April 8th 2025

Gene therapy shows encouraging efficacy for overactive bladder

Hannah Clarke
At week 12, patients in the URO-902 cohorts demonstrated significantly greater improvements in daily microuritions vs placebo.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
FDA grants 510(k) clearance to Glean Urodynamics System
April 2nd 2025

FDA grants 510(k) clearance to Glean Urodynamics System

Hannah Clarke
"Glean will enable patients to void naturally, without catheters in place. I believe this advance will yield a better test that mimics actual symptoms," says Bilal I. Chughtai, MD.
Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury
March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke
The 52-week study plans to enroll 16 patients across 4 sites in the US.
© 2025 MJH Life Sciences

All rights reserved.